A Phase I, Open-Label, Multicenter, Dose-escalation, Multidose Study of MDX-1411 Administered Every 7 Days in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia or Mantle Cell Lymphoma
Dose-escalation, multidose study of MDX-1411, a fully human nonfucosylated monoclonal
antibody (mAb) targeting the CD70 transmembrane cell-surface protein, which is highly
expressed in B-cell malignancies such as CLL and MCL.
Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Safety Profile of MDX-1411 and determine the maximum tolerated dose (MTD)
Medarex Medical Monitor
United States: Food and Drug Administration